In August, the FDA said early data suggested KP.3.1.1 might have substantially reduced susceptibility to Pemgarda. At the time, the variant accounted for 36.8% of COVID-19 infections.
A month later, with KP.3.1.1’s dominance at 52.7%, the FDA confirmed Sept. 26 in an email alert that the drug “is likely to retain adequate neutralization activity.”
Pemgarda (pemivibart) is authorized for the pre-exposure prophylaxis of COVID-19 in some adults and children older than 12. Eligible patients are those who have a moderate to severe immune compromise and are unlikely to have an adequate response to a COVID-19 vaccine.
The agency said it will continue to provide updates on Pemgarda’s efficacy against circulating variants.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
